Skip to content
Search

Latest Stories

Submit Guest Post

'Pharmacy of the world' India exports first covid vaccines

'Pharmacy of the world' India exports first covid vaccines

India exported its first batch of locally produced coronavirus shots on Wednesday (20), officials said, as the world's biggest vaccine manufacturer scrambled to meet requests from other countries desperate to protect their populations.

The Maldives and Bhutan will be the first recipients of India's coronavirus vaccine, while Brazil and South Africa are also among those on the waiting list.


Foreign minister S. Jaishankar said on Twitter that the "Pharmacy of the World will deliver to overcome the COVID challenge".

The policy is seen in part as a push by India to boost its soft power and take on rival China, which is also supplying vaccines to other countries.

In January, Indian regulators approved two vaccines -- one, Covishield, developed by AstraZeneca and Oxford University and produced by India's Serum Institute, and the other Covaxin, made by local firm Bharat Biotech.

The Indian government said the Maldives will receive a free supply of 100,000 doses of Covishield on Wednesday, while Bhutan will receive 150,000 as a "gift".

Bangladesh, Nepal, Myanmar and Seychelles will follow shortly, New Dehli said.

India plans to offer 20 million doses to its South Asian neighbours, Bloomberg News reported last week, with others in Latin America, Africa and Central Asia next in line.

The Serum Institute, the world's biggest vaccine maker by volume, also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.

Meanwhile, Covaxin's maker Bharat Biotech last week signed a deal with a Brazilian firm and is ramping up annual production to 700 million doses, a spokesperson told financial outlet the Mint Daily on Wednesday.

India on Saturday began rolling out Covishield and Covaxin jabs to its 1.3 billion people, although the shot for the latter is yet to complete human trials.

As of Wednesday, India had vaccinated almost 675,000 people, according to the government, as it pushes to inoculate 300 million people by July.

But amid some public scepticism and technical problems, many people have not been showing up at appointments to get their first shot.

In the first two days of the rollout in the capital New Delhi, for instance, only 53 percent of people invited came forward for jabs, the city's health minister Satyendar Jain said.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

capitals jingle bell ball ticket bookings

Capital's Jingle Bell Ball returns to London for two nights of musical festivity in December 2026

Instagram/Capitalofficial

Capital’s Jingle Bell Ball 2026: Ticket sale dates and how to buy

Highlights

  • Capital's Jingle Bell Ball returns to London's The O2 on December 5 and 6.
  • Pre-sale tickets open at 9am on November 5, with early access for subscribers and Barclaycard holders.
  • General sale begins at 9am on November 6 through Global Player.


Where is Capital's Jingle Bell Ball 2026 taking place?

The two-night event will return to The O2 arena in London, with doors opening at 4.30pm on both days. Performances are scheduled to begin at 6 pm and finish at approximately 10 pm. Fans who cannot attend should also keep an eye on Capital and Global Player for updates on the event and any viewing options.


Everything you need to know about getting tickets

Capital's Jingle Bell Ball is returning to London this December, bringing two nights of live music to The O2. With tickets going on sale this week, fans will have several ways to secure their tickets for the annual festive music event. The 2026 edition will take place on Saturday, December 5, and Sunday, December 6. The full line-up will be revealed on Capital Breakfast with Jordan North, Chris Stark and Siân Welby on November 4 and 5, from 7 am.

When do Capital Jingle Bell Ball 2026 tickets go on sale?
Tickets will be available through two main sales.

Keep ReadingShow less